CHIDAMIDE

作品数：25被引量：46H指数：5
导出分析报告
相关领域：医药卫生更多>>
相关作者：王利军王新莉蔡真靖彧于力更多>>
相关机构：中国人民解放军总医院南方医科大学沈阳医学院浙江大学医学院附属第一医院更多>>
相关期刊：《天津医科大学学报》《Advances in Modern Oncology Research》《临床血液学杂志》《Medicinal Plant》更多>>
相关基金：国家自然科学基金辽宁省教育厅科技项目更多>>
-
在结果中检索

检索结果分析

结果分析中...
共 条 记 录，以下是1-10
全选清除导出
参考文献引证文献引用追踪
视图：
排序：
Anti-PD-L1 antibody ASC22 in combination with a histone deacetylase inhibitor chidamide as a “shock and kill” strategy for ART-free virological control: a phase Ⅱ single-arm study
《Signal Transduction and Targeted Therapy》2024年第10期4579-4589,共11页Luling Wu Zhihang Zheng Jingna Xun Li Liu Jiangrong Wang Xinyu Zhang Yueming Shao Yinzhong Shen Renfang Zhang Min Zhang Meiyan Sun Tangkai Qi Zhenyan Wang Shuibao Xu Wei Song Yang Tang Bihe Zhao Zichen Song Jean-Pierre Routy Hongzhou Lu Jun Chen 
Ascletis Pharma Inc.and the Shanghai Commission of Science and Technology(grant no.20MC1920100,grant no.20Y31900400 and grant no.21Y11901200)。
The combination of ASC22, an anti-PD-L1 antibody potentially enhancing HIV-specific immunity and chidamide, a HIV latency reversal agent, may serve as a strategy for antiretroviral therapy-free virological control for...
关键词：IMMUNITY alterations treatment 
Chidamide plus prednisone,cyclophosphamide,and thalidomide for relapsed or refractory peripheral T-cell lymphoma:A multicenter phase II trial
《Chinese Medical Journal》2024年第13期1576-1582,共7页Jinhua Liang Li Wang Xiaodong Wang Guohui Cui Jianfeng Zhou Tongyao Xing Kaixin Du Jingyan Xu Luqun Wang Rong Liang Biyun Chen Jian Cheng Haorui Shen Jianyong Li Wei Xu 
National Natural Science Foundation of China(Nos.81770166,81700193,82170186,and 81720108002);Jiangsu Province’s Medical Elite Programme(No.ZDRCA2016022);Project of the National Key Clinical Specialty,the Jiangsu Provincial Special Program of Medical Science(No.BE2017751);National Science and Technology Major Project(No.2018ZX09734007);China Postdoctoral Science Foundation(No.2021M691336);Jiangsu Postdoctoral Science Foundation(No.2021K083A)
Background:Although the treatment of peripheral T-cell lymphoma(PTCL)has undergone advancements during the past several years,the response rate and long-term effects with respect to patients with PTCL remain unsatisfa...
关键词：Peripheral T-cell lymphoma CHIDAMIDE PREDNISONE CYCLOPHOSPHAMIDE THALIDOMIDE All-oral regimen 
Sintilimab(anti-PD-1 antibody)plus chidamide(histone deacetylase inhibitor)in relapsed or refractory extranodal natural killer T-cell lymphoma(SCENT):a phase Ⅰb/Ⅱ study被引量：3
《Signal Transduction and Targeted Therapy》2024年第6期2765-2773,共9页Yan Gao Haixia He Xueping Li Liling Zhang Wei Xu Ru Feng Wenyu Li Yin Xiao Xinxiu Liu Yu Chen Xiaoxiao Wang Bing Bai Huijing Wu Qingqing Cai Zhiming Li Jibin Li Suxia Lin Yanxia He Liqin Ping Cheng Huang Jiaying Mao Xiujin Chen Baitian Zhao Huiqiang Huang 
supported by the National Natural Science Foundation of China(grant numbers 82170188 and 81970176);Guangdong Basic and Applied Basic Research Foundation(grant number 2021A1515110012).
Anti-PD-1 antibodies are a favorable treatment for relapsed or refractory extranodal natural killer T cell lymphoma(RR-ENKTL),however,the complete response(CR)rate and the duration of response(DOR)need to be improved....
关键词：KILLER LYMPHOMA doses 
Chidamide,Decitabine,Cytarabine,Aclarubicin,and Granulocyte Colony-stimulating Factor Therapy for Patients with Relapsed/Refractory Acute Myeloid Leukemia:A Retrospective Study from a Single-Center
《Current Medical Science》2023年第6期1151-1161,共11页Fan-cong KONG Ling QI Yu-lan ZHOU Min YU Wen-feng HUANG Fei LI 
the National Natural Science Foundation of China(No.81960043 and No.81600180);Natural Science Foundation of Jiangxi Province(No.20192ACB20030 and No.20203BBGL73197);Science and Technology Innovation Base Construction Project of Jiangxi Province(No.20212BCG74001 and No.20211ZDG02006).
Objective Preclinical evidence and clinical trials have suggested synergistic effects of epigenetic modifiers in combination with cytotoxic agents for the treatment of leukemia.However,their efficacy in patients with ...
关键词：relapsed/refractory acute myeloid leukemia histone deacetylase inhibitor DNA methyltransferase inhibitor salvage therapy 
Chidamide-BEAC plus autologous stem cell transplantation in high-risk non-Hodgkin lymphoma:a phase II clinical trial被引量：2
《Chinese Medical Journal》2023年第12期1491-1493,共3页Yi Xia Li Wang Kaiyang Ding Jiazhu Wu Hua Yin Maogui Hu Haorui Shen Jinhua Liang Ruize Chen Yue Li Huayuan Zhu Jianyong Li Wei Xu 
National Natural Science Foundation of China(Nos.81770166,81700193,82170186 and 81720108002);Jiangsu Province’s Medical Elite Programme(No.ZDRCA2016022);Project of National Key Clinical Specialty,Jiangsu Provincial Special Program of Medical Science(No.BE2017751);National Science and Technology Major Project(No.2018 ZX09734007);China Postdoctoral Science Foundation(No.2021M691336);Jiangsu Postdoctoral Science Foundation(No.2021K083A);Translational Research Grant of NCRCH(No.2020ZKZB01)
To the Editor:Non-Hodgkin lymphoma(NHL)is a common type of hematological malignancy.Although the development of targeted therapies has improved the survival of patients with aggressive NHL,autologous hematopoietic ste...
关键词：AUTOLOGOUS LYMPHOMA NHL 
组蛋白去乙酰化酶抑制剂Chidamide抑制C2C12骨骼肌细胞分化及其机制
《天津医科大学学报》2023年第2期142-147,共6页张露露 郭洋 王新莉 牛文彦 
天津市教委科研计划(2017KJ212)。
目的:探讨组蛋白去乙酰化酶抑制剂西达苯胺(Chidamide)对C2C12小鼠骨骼肌细胞分化作用及其分子机制。方法:CCK-8(cell counting Kit-8)法检测0、0.5、1、2、4μmol/L Chidamide处理后C2C12细胞的活力;将C2C12骨骼肌细胞分为对照组(contr...
关键词：组蛋白去乙酰化酶抑制剂 骨骼肌 肌原纤维 分化 
Noncirrhotic portal hypertension due to peripheral T-cell lymphoma,not otherwise specified:A case report
《World Journal of Clinical Cases》2022年第26期9417-9427,共11页Miao-Miao Wu Wen-Jun Fu Jia Wu Lin-Lin Zhu Ting Niu Rong Yang Jin Yao Qiang Lu Xiao-Yang Liao 
BACKGROUND Peripheral T-cell lymphoma(PTCL),an aggressive and rare disease that belongs to a heterogeneous group of mature T-cell lymphomas,develops rapidly and has a poor prognosis.Early detection and treatment are e...
关键词：Noncirrhotic portal hypertension ASCITES Peripheral T-cell lymphoma LYMPHOMA CHIDAMIDE Case report 
HDAC inhibitor chidamide synergizes with venetoclax to inhibit the growth of diffuse large B-cell lymphoma via down-regulation of MYC, BCL2, and TP53 expression被引量：2
《Journal of Zhejiang University-Science B(Biomedicine & Biotechnology)》2022年第8期666-681,共16页Cancan LUO Tiantian YU Ken H.YOUNG Li Yu 
supported by the National Natural Science Foundation of China(Nos.81460030 and 81770221)。
Diffuse large B-cell lymphoma(DLBCL) is an aggressive type of non-Hodgkin’s lymphoma. A total of 10%-15% of DLBCL cases are associated with myelocytomatosis viral oncogene homolog(MYC) and/or B-cell lymphoma-2(BCL2) ...
关键词：Diffuse large B-cell lymphoma(DLBCL) Histone deacetylase(HDAC)inhibitor Venetoclax MYC BCL2 TP53 
Chidamide and sintilimab combination in diffuse large B-cell lymphoma progressing after chimeric antigen receptor T therapy
《World Journal of Clinical Cases》2022年第19期6555-6562,共8页Yuan-Yuan Hao Pan-Pan Chen Xiang-Gui Yuan Ai-Qi Zhao Yun Liang Hui Liu Wen-Bin Qian 
BACKGROUND Diffuse large B-cell lymphoma(DLBCL)is curable with first-line chemoimmunotherapy but patients with relapsed/refractory(R/R)DLBCL still face a poor prognosis.For patients with R/R DLBCL,the complete respons...
关键词：Chimeric antigen receptor T cell therapy Diffuse large B-cell lymphoma IMMUNOTHERAPY PD-1 inhibitor Histone deacetylase inhibitor Case report 
Chidamide inhibits the NOTCH1-MYC signaling axis in T-cell acute lymphoblastic leukemia被引量：3
《Frontiers of Medicine》2022年第3期442-458,共17页Mengping Xi Shanshan Guo Caicike Bayin Lijun peng Florent Chuffart Ekaterina Bourova-Flin Sophie Rousseaux Saadi Khochbin Jian-Qing Mi Jin Wang 
This study was fiunded by the Shanghai Science and Technology Commitee(No.21430711800),National Natural Science Founda-tion of China(Nos.81670147,81570178,and Antrag M-0377);Gaofeng Clinical Medicine Grant Support of Shanghai Municipal Education No.20172002);Shanghai Municipal Education Com-mission-Major Project for Scientifc Research and Innovation Plan of Natural Science(No.2021-01-07-00-02-E00091).SK laboratory is supported by"Fondation ARC"grant(PGA1RF20190208471)and the ANR EpiSperm 4 program.Additional supports were fom the"Universite Grenoble Alpes"ANR-15-IDEX-02 LIFE and SYMER programs,as well as the INSERMTTMO/Aviesan MIC 2021 program(roject ECTOCAN).
T-cell acute lymphoblastic leukemia(T-ALL)is one of the most dangerous hematological malignancies,with high tumor heterogeneity and poor prognosis.More than 60%of T-ALL patients carry NOTCH1 gene mutations,leading to ...
关键词：T-cell acute lymphoblastic leukemia HDAC inhibitor CHIDAMIDE NOTCH1 MYC UBIQUITINATION 
全选清除导出
共3页<123>
检索报告 对象比较 聚类工具 使用帮助 返回顶部